Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Lupin
Large Cap•19,210 Employees•IPO 1994
Current Price
₹2311.10
9.2 (0.4%)Updated
Today's Range
₹2261.30
₹2322.40
₹2311.10
52 Week Range
52W Low₹1795.20
52W High₹2336.30
₹2311.10
Downside28.74%
Upside1.09%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹1,02,717.25 Cr
Market Cap
Total market value of companyP/E Ratio
22.11
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
4.45
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹108.62
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
12.22%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
21.30%
ROCE
Return on Capital Employed. >15% is goodNet Margin
17.76%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
8.11%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
11.90%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
52.10%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.32
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹376.80
Book Value
Net asset value per shareDividend Yield
0.53%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
46.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Lupin Ltd exhibits strong profitability, with a Return on Equity (ROE) of 20.6% and a healthy Operating Profit Margin (OPM) of 24.6%, indicating efficient operations and high returns on investment.
- •The company shows impressive quarterly profit growth, with a 52.1% increase. This positive trend suggests strong demand for its products and effective management strategies.
Weaknesses
3 points- •Lupin's stock price has shown recent volatility, with a 52-week high of ₹2403 and a low of ₹1774, indicating potential market risk and requiring close monitoring.
- •The company's total debt stands at ₹5448 crore. While the debt-to-equity ratio is low, this absolute debt figure could pose a risk if not managed effectively.
Opportunities
4 points- •Increasing institutional investor confidence is evident, with FII holdings rising from 13.32% (Mar 2023) to 20.50% (Sept 2025), signaling positive sentiment and potential for further investment.
- •Lupin's current PE ratio of 24.20 is lower than several peers like Divi's Lab (74.70) and Torrent Pharma (60.11), suggesting potential for a valuation re-rating if growth continues.
Threats
3 points- •Intense competition from larger peers like Sun Pharma (Market Cap ₹412445 Cr) and Cipla (Market Cap ₹127764 Cr) could pressure Lupin's market share and pricing power.
- •Lupin faces competitive pressure from peers with higher ROCE, such as Torrent Pharma (27.05%) and Zydus Lifesci (24.31%), potentially impacting its relative market position and profitability.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹2457.43 | +₹146.33 | +6.33% |
| R3 | ₹2396.33 | +₹85.23 | +3.69% |
| R2 | ₹2359.37 | +₹48.27 | +2.09% |
| R1 | ₹2335.23 | +₹24.13 | +1.04% |
| PIVOT | ₹2298.27 | -12.83 | -0.56% |
| CURRENT | ₹2311.10 | - | - |
| S1 | ₹2151.93 | -₹159.17 | -6.89% |
| S2 | ₹2213.03 | -₹98.07 | -4.24% |
| S3 | ₹2237.17 | -₹73.93 | -3.20% |
| S4 | ₹2274.13 | -₹36.97 | -1.60% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-30.2% vs avg
5.81L
(02 Mar 2026)Delivery %-4.0% vs avg
47.0%
(02 Mar 2026)Avg Volume (20D)20-day average
8.32L
(03 Feb - 02 Mar)Avg Delivery %Trend ↑
51.0%
(03 Feb - 02 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %
Peer Comparison
| Company Name |
|---|
 Abbott India Ltd |
 Alkem Laboratories Ltd |
 Aurobindo Pharma Ltd |
 Cipla Ltd |
 Dr Reddys Laboratories Ltd |
 Glaxosmithkline Pharmaceuticals Ltd |
 Glenmark Pharmaceuticals Ltd |
 Laurus Labs Ltd |
 Mankind Pharma Ltd |
 Sun Pharmaceutical Industries Ltd |
 Torrent Pharmaceuticals Ltd |
 Zydus Lifesciences Ltd |
About
Lupin Ltd
Lupin Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with a global presence. Established in 1968 (formerly Lupin Chemicals Limited), the company's core business involves the entire pharmaceutical value chain, from drug discovery and development to manufacturing, marketing, and sales.
Lupin's product portfolio is extensive and diverse, encompassing branded and generic formulations, biosimilars, over-the-counter medications, and specialty drugs. A significant portion of their business centers around the production and supply of Active Pharmaceutical Ingredients (APIs), the fundamental building blocks of many pharmaceutical products. This vertical integration allows for greater control over quality and cost.
The company caters to a wide range of therapeutic areas, reflecting a commitment to addressing diverse health needs. These areas include, but are not limited to, anti-tuberculosis treatments, diabetes management, cardiovascular health, respiratory diseases (COPD and asthma), women's health, central nervous system disorders, oncology, immunology, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal health, anti-infective therapies, and nonsteroidal anti-inflammatory drugs. This broad therapeutic focus positions Lupin as a significant player in the global pharmaceutical market.
Beyond its core manufacturing and distribution activities, Lupin is also engaged in bio-clinical research. This commitment to research and development underpins their ability to innovate and bring new and improved treatments to market. Furthermore, the company's operational network includes laboratories, collection centers (LupiMitra), and pickup points, suggesting a robust infrastructure designed to support its extensive operations and reach a wide patient base.
COMPANY FACTS - LUPIN
Registered Address
3rd Floor, Kalpataru Inspire,, Off. Western Expressway Highway,, Santacruz (East),
Mumbai
MAHARASHTRA
IN
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 19,210
IPO Date: 30/11/1994
MANAGEMENT - LUPIN
Mrs. Manju Gupta
Non-Executive Chairman of the Board
Ms. Vinita Gupta
Chief Executive Officer, Executive Director
Mr. Ramesh Swaminathan
Executive Director, Global Chief Financial Officer, Chief Risk Officer and Head of API Plus SBU
Mr. Rajendra Chunodkar
President - Manufacturing Operations
Dr. Fabrice Egros
President - Corporate Development and Growth Markets
Mr. Spiro Gavaris
President - U.S. Generics
Mr. Naresh Gupta
President - API Plus and Global TB
Mr. Claus Jepsen
President - Global Specialty
Dr. Rajender Kamboj
President - Novel Drug Discovery and Development
Dr. Cyrus Karkaria
President - Biotechnology
Mr. Sunil Makharia
President - Finance
Dr. Sofia Mumtaz
President - Legal, Canada and APAC
Investor Questions Answered
Lupin Ltd (LUPIN) Stock FAQs
Get answers to the most common questions about Lupin Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Lupin Ltd (LUPIN) is ₹2,311.1. Today, the stock has gained by ₹9.20 (0.40%), trading in a range of ₹2,261.3 to ₹2,322.4. The stock opened at ₹2,275.6 with a trading volume of 5,80,930 shares.
Lupin Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,02,717.25 crores, P/E ratio of 22.11, ROE of 12.22%, and ROCE of 21.30%. The dividend yield stands at 0.53%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Lupin Ltd (LUPIN) is ₹2,336.3, while the 52-week low is ₹1,795.2. Currently trading at ₹2,311.1, the stock is 95.3% away from its 52-week low and 1.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Lupin Ltd stock at ₹2,311.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 22.11 and P/B ratio of N/A. Today's performance shows a gain of 0.40%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Lupin Ltd offers a dividend yield of 0.53%, which means for every ₹100 invested at the current price of ₹2,311.1, you can expect to receive approximately ₹0.53 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Lupin Ltd's key financial metrics include: P/E Ratio: 22.11, P/B Ratio: N/A, ROE: 12.22%, ROCE: 21.30%, Dividend Yield: 0.53%, EPS: ₹108.62, Book Value: ₹376.8, Debt-to-Equity: 0.32, and Current Ratio: N/A. The company's market cap stands at ₹1,02,717.25 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Lupin Ltd stock opened at ₹2,275.6 and is currently trading at ₹2,311.1, showing a gain of ₹9.20 (0.40%). The intraday high is ₹2,322.4 and low is ₹2,261.3. The trading volume stands at 5,80,930 shares, indicating moderate market participation today.
Lupin Ltd has a Price-to-Earnings (P/E) ratio of 22.11, which means investors are willing to pay ₹22.11 for every ₹1 of earnings. With an EPS of ₹108.62, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Lupin Ltd has a market capitalization of ₹1,02,717.25 crores, making it a large-cap company. Market cap is calculated by multiplying the current stock price (₹2,311.1) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Lupin Ltd has a book value of ₹376.8 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹2,311.1, which is 513.3% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Lupin Ltd has a Return on Equity (ROE) of 12.22% and Return on Capital Employed (ROCE) of 21.30%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
Lupin Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Lupin Ltd has a debt-to-equity ratio of 0.32, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Lupin Ltd has an Earnings Per Share (EPS) of ₹108.62, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹2,311.1 and P/E ratio of 22.11, investors are paying 22.11 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Lupin Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Lupin Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Lupin Ltd stock, consider: 1) Fundamental Analysis - Review P/E (22.11), ROE (12.22%), debt-to-equity (0.32), and growth rates. 2) Technical Analysis - Check 52-week range (₹1795.20 - ₹2336.30), moving averages, and chart patterns. 3) Valuation - Compare current price (₹2311.10) with book value (₹376.80) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Lupin Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹2,311.1 is 115455x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Lupin Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1795.20 - ₹2336.30). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.32 indicates leverage. 4) Liquidity Risk - Based on trading volume of 5,80,930 shares. 5) Valuation Risk - P/E of 22.11 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Lupin Ltd operates in the industry with key metrics: P/E ratio of 22.11, ROE of 12.22%, market cap of ₹1,02,717.25 crores, and dividend yield of 0.53%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.32), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Lupin Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹2,311.1, with a 52-week range of ₹1795.20 to ₹2336.30. Based on fundamentals like P/E (22.11), ROE (12.22%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Lupin Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹2311.10. 2) Fundamental Deterioration - Declining ROE (currently 12.22%), increasing debt (D/E: 0.32), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Lupin Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.53%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu